Marisa Wexler, MS,  senior science writer—

A new Phase 3 clinical trial testing Kyverna Therapeutics’ cell therapy candidate KYV-101 in people with myasthenia gravis (MG) — a study the developer says “supports [a] clear and rapid path to [regulatory approval]” — is expected to start enrolling participants before the end of the year, according to…

Two genes that help to control the human body’s biological clock are dysregulated in myasthenia gravis (MG) — a disease marked by symptoms that often grow worse throughout the day — according to the findings of a new study from China. Study data indicated that dysregulation of these genes,…

Treatment with gefurulimab, an experimental self-administered injection therapy, outperformed a placebo in easing symptoms of generalized myasthenia gravis (gMG) among people with the chronic autoimmune disease, the results of a Phase 3 clinical trial show. The trial met both its primary and secondary endpoints, or goals, with treatment…

Remegen’s telitacicept has been approved in China as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — that’s approximately 80% of all gMG patients, per the company. The decision, by the country’s National Medical Products Administration…

A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly 30 out of every 1 million children in the U.S., and may be more common than previously thought, a study estimates. The study also found that JMG is more common…

Kyverna Therapeutics is planning to launch a Phase 3 clinical trial testing its experimental cell therapy KYV-101 in people with myasthenia gravis (MG). The announcement follows an end-of-Phase 2 meeting between Kyverna and the U.S. Food and Drug Administration (FDA). According to the company, the FDA has…

Cartesian Therapeutics is gearing up for two clinical trials of its cell therapy Descartes-08: the first, a Phase 3 study, will enroll adults with myasthenia gravis (MG), while the second, a Phase 2 basket trial, will test the treatment candidate in children with juvenile MG and other…

Japan’s drug regulatory agency has authorized two new administration methods for Rystiggo (rozanolixizumab) — an approved treatment for generalized myasthenia gravis (gMG) — that people with the chronic autoimmune condition can use at home. These approvals, by the Pharmaceuticals and Medical Devices Agency, or PMDA, will allow gMG…

Enrollment is now complete for a Phase 2 clinical trial testing Dianthus Therapeutics‘ treatment candidate DNTH103 in people with generalized myasthenia gravis (gMG). According to the developer, the initial results from the global study, dubbed MAGIC (NCT06282159), are expected by early fall. MAGIC was launched early…

Levels of antibodies against muscle-specific kinase (MuSK) are not reflective of disease severity in people with MuSK-positive myasthenia gravis (MG), according to a study. “Given our results, MuSK autoantibodies are not suitable as biomarkers for clinical severity or prognosis in MuSK-positive MG,” the researchers wrote. The study, “…